insights_auto
Outlook: Optimistická perspektíva: 48.6 %·Pesimistická perspektíva: 0.0 %
Prejsť na analýzuchevron_right
GILD:NASDAQ
Gilead Sciences
156,19 USD
arrow_downward
-0,75%(-1,18) 1 d.
156,84 USD
arrow_upward
+0,42% (+0,65)bedtimePo uzavretí
Zavreté: 16. 10., 16:00:02 GMT-4 · USD
search
Všetky symboly
| Symbol | Cena | Zmena | % zmeny |
|---|
insights_autoGenerujú sa najdôležitejšie štatistiky pre GILD…
Otvoriť
157,32 USD
Vysoká
157,58 USD
Nízka
155,62 USD
Trh. kap.
193,67 mld.
Priem. obj.
5,79 mil.
Objem
7,77 mil.
Dividenda
2,10 %
Štvrťročná dividenda
0,82 USD
Prvý obchodný deň po vyplatení dividendy
15. 9. 2026
Max. za 52 týž.
160,51 USD
Min. za 52 týž.
114,02 USD
Výnosy na akciu
-2,66 USD
Beta
0,32
Akcie v obehu
1,24 mld.
Počet zamestnancov
17 tis.
Otvoriť
157,32 USD
Vysoká
157,58 USD
Nízka
155,62 USD
Trh. kap.
193,67 mld.
Priem. obj.
5,79 mil.
Objem
7,77 mil.
Dividenda
2,10 %
Štvrťročná dividenda
0,82 USD
Prvý obchodný deň po vyplatení dividendy
15. 9. 2026
Max. za 52 týž.
160,51 USD
Min. za 52 týž.
114,02 USD
Výnosy na akciu
-2,66 USD
Beta
0,32
Akcie v obehu
1,24 mld.
Počet zamestnancov
17 tis.
Spravodajstvo
Z internetových zdrojov a od spravodajských partnerov
Simply Wall Street
·
pred 8 hodinami
Did Cancer Drug Partnership Just Shift Gilead's (GILD) Investment Narrative?
Investing.com Nigeria
·
pred 10 hodinami
Gilead chairman & CEO O’Day sells $2.2m in stock
MarketBeat
·
pred 13 hodinami
Gilead Sciences, Inc. $GILD Stock Sold by New England Research & Management Inc.
Investing.com Nigeria
·
pred 21 hodinami
Gilead chief comm & corp aff officer sells $468,660 in GILD shares
Profil
Gilead Sciences, Inc. is an American biopharmaceutical company headquartered in Foster City, California, that focuses on researching and developing antiviral drugs used in the treatment of HIV/AIDS, hepatitis B, hepatitis C, influenza, and COVID-19. It also develops medicines in therapeutic areas such as oncology and inflammation and cell therapy.
In 1987, Michael L. Riordan founded the company under the name Oligogen. The original name was a reference to oligonucleotides, small strands of DNA used to target genetic sequences. Gilead held its initial public offering in 1992, and successfully developed drugs including Tamiflu and Vistide that decade.
In the 2000s, Gilead began evolving from a biotechnology company into a large pharmaceutical company, through acquisitions and investments, acquiring several subsidiaries. Gilead is a member of the Nasdaq-100 and the S&P 100.
The company has faced criticism over its business practices, including extremely high pricing of drugs such as Sovaldi and Truvada in the United States relative to production cost and cost in the developing world. Wikipedia
Informácie o subjekte Gilead Sciences
Generálny riaditeľDaniel O'Day
Zamestnanci17 tis.
Dátum založenia22. 6. 1987
Hlavné sídloFoster City, Kalifornia, Spojené štáty americké
Odvetvie-
Webgilead.com